Clinical Trials Logo

Cholangiocarcinoma, Intrahepatic clinical trials

View clinical trials related to Cholangiocarcinoma, Intrahepatic.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06381648 Recruiting - Cholangiocarcinoma Clinical Trials

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

LyMIC
Start date: April 15, 2023
Phase:
Study type: Observational

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

NCT ID: NCT06140134 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Liver Transplantation in Intrahepatic Cholangiocarcinoma

Start date: December 15, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the current study is to determine the potential efficacy of liver transplantation in the form of patients' overall survival (OS) after neoadjuvant systemic therapy in patients with biologically responsive locally advanced non-metastatic intrahepatic cholangiocarcinoma (iCCA) in comparison to patients historically treated with chemotherapy alone.

NCT ID: NCT05210322 Recruiting - Cholelithiasis Clinical Trials

Percutaneous Cholangiopancreatoscopy Registry

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

The Percutaneous Cholangiopancreatoscopy (PCPS) registry is an observational, multicentric, prospective, and retrospective registry of patients undergoing the percutaneous cholangiopancreatoscopy procedure at sites across the United States. In the retrospective component of the study, clinical and procedural data regarding patients who have undergone clinical indicated percutaneous cholangiopancreatoscopy procedure in the past will be collected from all the registry sites and stored in a secure database. The prospective component of the registry will run for three years at each site where patients undergoing the clinically indicated percutaneous cholangiopancreatoscopy procedure will be enrolled in the study, and the patients' data will be collected whenever the patients present to interventional radiology (IR) for a procedure or clinic visit.

NCT ID: NCT05124002 Recruiting - Clinical trials for Cholangiocarcinoma, Intrahepatic

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Start date: August 1, 2022
Phase: Phase 4
Study type: Interventional

Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor effects on liver cancer. This study aims to further verify the effect and safety of recombinant human adenovirus type 5 combined with HAIC in the treatment of intrahepatic mass-forming cholangiocarcinoma.

NCT ID: NCT04782804 Recruiting - Clinical trials for Cholangiocarcinoma, Intrahepatic

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Start date: January 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to observe the effect of PD-1 Antibody(Tislelizumab) Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.

NCT ID: NCT04634058 Recruiting - Clinical trials for Cholangiocarcinoma, Intrahepatic

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the efficacy and safety of PD-L1 antibody combined with the CTLA-4 antibody in patients with advanced ICC who progressed after standard treatment.

NCT ID: NCT04506281 Recruiting - Clinical trials for Cholangiocarcinoma, Intrahepatic

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim to compare the prognosis in intrahepatic cholangiocarcinoma between Toripalimab combined with Lenvatinib and GEMOX neoadjuvant treatment and the current clinical surgical treatment (traditional group).

NCT ID: NCT04264260 Recruiting - Clinical trials for Cholangiocarcinoma, Intrahepatic

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

Start date: December 24, 2019
Phase: Phase 2
Study type: Interventional

This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration. Colchicine will be started from 2 tablets after meal twice per day (total 2 mg), adjust the dose ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated treatment cycles till the participants quit the trial. The control group will be originated from review of (1) patients treated by members of this research team with the same condition as the trial selected participants but not included in the trial, (2) patients with same condition as the trial selected participants reported in the literatures. The primary objective is to evaluate the palliative effects of colchicine on primary hepatic malignancy unable to receive curative treatment. The primary end point is survival of the participant. The Secondary objective is to evaluate the safety of patients treated by colchicine and the secondary end point is the side effects of colchicine.